Eli Lilly steps into vaccine development with $3.83B triple takeover
Eli Lilly and Company is pivoting significantly toward infectious disease prevention by executing agreements to buy three distinct vaccine developers. Funded by the massive financial windfalls from its dominant obesity and diabetes medications, the Indianapolis-based pharmaceutical giant is deploying up… Read More »Eli Lilly steps into vaccine development with $3.83B triple takeover



